fenofibrate has been researched along with Aortic Aneurysm, Abdominal in 10 studies
Pharmavit: a polyvitamin product, comprising vitamins A, D2, B1, B2, B6, C, E, nicotinamide, & calcium pantothene; may be a promising agent for application to human populations exposed to carcinogenic and genetic hazards of ionizing radiation; RN from CHEMLINE
Aortic Aneurysm, Abdominal: An abnormal balloon- or sac-like dilatation in the wall of the ABDOMINAL AORTA which gives rise to the visceral, the parietal, and the terminal (iliac) branches below the aortic hiatus at the diaphragm.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Experimental studies suggest that fenofibrate prevents abdominal aortic aneurysm (AAA) development by lowering aortic osteopontin (OPN) concentration and reducing the number of macrophages infiltrating the aortic wall." | 9.34 | A Randomised Controlled Trial Assessing the Effects of Peri-operative Fenofibrate Administration on Abdominal Aortic Aneurysm Pathology: Outcomes From the FAME Trial. ( Cavaye, D; Golledge, J; Jaeggi, R; Jenkins, JS; Lazzaroni, SM; Moran, CS; Morton, SK; Moxon, JV; Pinchbeck, JL; Quigley, F; Reid, CM; Rowbotham, SE, 2020) |
| "Fenofibrate in the management of AbdoMinal aortic anEurysm (FAME) is a multicentre, randomised, double-blind, placebo-controlled clinical trial to assess the effect of orally administered therapy with fenofibrate on key pathological markers of AAA in patients undergoing open AAA repair." | 9.24 | Fenofibrate in the management of AbdoMinal aortic anEurysm (FAME): study protocol for a randomised controlled trial. ( Cavaye, D; Golledge, J; Jaeggi, R; Jenkins, JS; Moran, CS; Moxon, JV; Pinchbeck, JL; Quigley, F; Reid, CM; Rowbotham, SE, 2017) |
| "This mini-review provides the rationale and updated progress for ongoing randomized controlled trials assessing fenofibrate and telmisartan efficacy to limit abdominal aortic aneurysm (AAA) growth." | 8.98 | Fenofibrate and Telmisartan in the Management of Abdominal Aortic Aneurysm. ( Golledge, J; Krishna, SM; Moran, CS; Rowbotham, SE, 2018) |
| "The aims of this study were, firstly, to assess the effect of concurrent peripheral artery disease (PAD) on the health-related quality of life (QOL) of people diagnosed with a small abdominal aortic aneurysm (AAA); and secondly, to test whether the peroxisome proliferator-activated receptor α agonist fenofibrate improved QOL of people diagnosed with a small AAA, including those diagnosed with concurrent PAD." | 7.96 | Health-related quality of life amongst people diagnosed with abdominal aortic aneurysm and peripheral artery disease and the effect of fenofibrate. ( Golledge, J; Jenkins, JS; Moxon, JV; Pinchbeck, J; Quigley, F; Rowbotham, SE; Yip, L, 2020) |
| "Background There is no drug therapy for abdominal aortic aneurysm ( AAA )." | 6.87 | Randomized Placebo-Controlled Trial Assessing the Effect of 24-Week Fenofibrate Therapy on Circulating Markers of Abdominal Aortic Aneurysm: Outcomes From the FAME -2 Trial. ( Bourke, B; Bourke, M; Favot, D; Golledge, J; Hendy, K; Jaeggi, R; Jenkins, JS; Jones, RE; Lazzaroni, S; Matthews, EO; Morton, SK; Moxon, JV; Pinchbeck, JL; Quigley, F; Reid, CM; Rowbotham, SE; Velu, R, 2018) |
| "Experimental studies suggest that fenofibrate prevents abdominal aortic aneurysm (AAA) development by lowering aortic osteopontin (OPN) concentration and reducing the number of macrophages infiltrating the aortic wall." | 5.34 | A Randomised Controlled Trial Assessing the Effects of Peri-operative Fenofibrate Administration on Abdominal Aortic Aneurysm Pathology: Outcomes From the FAME Trial. ( Cavaye, D; Golledge, J; Jaeggi, R; Jenkins, JS; Lazzaroni, SM; Moran, CS; Morton, SK; Moxon, JV; Pinchbeck, JL; Quigley, F; Reid, CM; Rowbotham, SE, 2020) |
| "Fenofibrate in the management of AbdoMinal aortic anEurysm (FAME) is a multicentre, randomised, double-blind, placebo-controlled clinical trial to assess the effect of orally administered therapy with fenofibrate on key pathological markers of AAA in patients undergoing open AAA repair." | 5.24 | Fenofibrate in the management of AbdoMinal aortic anEurysm (FAME): study protocol for a randomised controlled trial. ( Cavaye, D; Golledge, J; Jaeggi, R; Jenkins, JS; Moran, CS; Moxon, JV; Pinchbeck, JL; Quigley, F; Reid, CM; Rowbotham, SE, 2017) |
| "This mini-review provides the rationale and updated progress for ongoing randomized controlled trials assessing fenofibrate and telmisartan efficacy to limit abdominal aortic aneurysm (AAA) growth." | 4.98 | Fenofibrate and Telmisartan in the Management of Abdominal Aortic Aneurysm. ( Golledge, J; Krishna, SM; Moran, CS; Rowbotham, SE, 2018) |
| "The aims of this study were, firstly, to assess the effect of concurrent peripheral artery disease (PAD) on the health-related quality of life (QOL) of people diagnosed with a small abdominal aortic aneurysm (AAA); and secondly, to test whether the peroxisome proliferator-activated receptor α agonist fenofibrate improved QOL of people diagnosed with a small AAA, including those diagnosed with concurrent PAD." | 3.96 | Health-related quality of life amongst people diagnosed with abdominal aortic aneurysm and peripheral artery disease and the effect of fenofibrate. ( Golledge, J; Jenkins, JS; Moxon, JV; Pinchbeck, J; Quigley, F; Rowbotham, SE; Yip, L, 2020) |
| "Background There is no drug therapy for abdominal aortic aneurysm ( AAA )." | 2.87 | Randomized Placebo-Controlled Trial Assessing the Effect of 24-Week Fenofibrate Therapy on Circulating Markers of Abdominal Aortic Aneurysm: Outcomes From the FAME -2 Trial. ( Bourke, B; Bourke, M; Favot, D; Golledge, J; Hendy, K; Jaeggi, R; Jenkins, JS; Jones, RE; Lazzaroni, S; Matthews, EO; Morton, SK; Moxon, JV; Pinchbeck, JL; Quigley, F; Reid, CM; Rowbotham, SE; Velu, R, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (60.00) | 24.3611 |
| 2020's | 4 (40.00) | 2.80 |
| Authors | Studies |
|---|---|
| Amioka, N | 1 |
| Miyoshi, T | 1 |
| Powell, JT | 1 |
| Moxon, JV | 5 |
| Rowbotham, SE | 5 |
| Pinchbeck, JL | 3 |
| Lazzaroni, SM | 1 |
| Morton, SK | 2 |
| Moran, CS | 4 |
| Quigley, F | 4 |
| Jenkins, JS | 4 |
| Reid, CM | 3 |
| Cavaye, D | 2 |
| Jaeggi, R | 3 |
| Golledge, J | 7 |
| Pinchbeck, J | 1 |
| Yip, L | 1 |
| Krishna, SM | 2 |
| Bourke, M | 1 |
| Lazzaroni, S | 1 |
| Matthews, EO | 1 |
| Hendy, K | 1 |
| Jones, RE | 1 |
| Bourke, B | 1 |
| Favot, D | 1 |
| Velu, R | 1 |
| Barshes, NR | 1 |
| Cullen, B | 1 |
| Rush, C | 2 |
| Secomb, E | 1 |
| Wood, F | 1 |
| Daugherty, A | 1 |
| Campbell, JH | 1 |
| Norman, PE | 2 |
| Seto, SW | 1 |
| Walker, PJ | 1 |
2 reviews available for fenofibrate and Aortic Aneurysm, Abdominal
| Article | Year |
|---|---|
Fibrates: A Possible Treatment Option for Patients with Abdominal Aortic Aneurysm?
Topics: Animals; Anti-Inflammatory Agents; Aorta, Abdominal; Aortic Aneurysm, Abdominal; Fenofibrate; Humans | 2022 |
Fenofibrate and Telmisartan in the Management of Abdominal Aortic Aneurysm.
Topics: Animals; Aortic Aneurysm, Abdominal; Down-Regulation; Fenofibrate; Humans; Osteopontin; PPAR gamma; | 2018 |
3 trials available for fenofibrate and Aortic Aneurysm, Abdominal
| Article | Year |
|---|---|
A Randomised Controlled Trial Assessing the Effects of Peri-operative Fenofibrate Administration on Abdominal Aortic Aneurysm Pathology: Outcomes From the FAME Trial.
Topics: Aged; Aorta, Abdominal; Aortic Aneurysm, Abdominal; Biomarkers; Disease Progression; Double-Blind Me | 2020 |
Randomized Placebo-Controlled Trial Assessing the Effect of 24-Week Fenofibrate Therapy on Circulating Markers of Abdominal Aortic Aneurysm: Outcomes From the FAME -2 Trial.
Topics: Aged; Aged, 80 and over; Aorta, Abdominal; Aortic Aneurysm, Abdominal; Biomarkers; Dose-Response Rel | 2018 |
Fenofibrate in the management of AbdoMinal aortic anEurysm (FAME): study protocol for a randomised controlled trial.
Topics: Administration, Oral; Aortic Aneurysm, Abdominal; Biomarkers; Clinical Protocols; Cytokines; Double- | 2017 |
5 other studies available for fenofibrate and Aortic Aneurysm, Abdominal
| Article | Year |
|---|---|
Lost in Translation From Mice to Men: Grief and Pain and FAME.
Topics: Animals; Aortic Aneurysm, Abdominal; Fenofibrate; Grief; Mice; Pain | 2020 |
Health-related quality of life amongst people diagnosed with abdominal aortic aneurysm and peripheral artery disease and the effect of fenofibrate.
Topics: Aged; Aged, 80 and over; Aortic Aneurysm, Abdominal; Case-Control Studies; Cross-Sectional Studies; | 2020 |
Nascent Medical Therapies for Abdominal Aneurysms.
Topics: Aortic Aneurysm, Abdominal; Aortic Rupture; Fenofibrate; Humans; Risk Factors | 2018 |
Peroxisome proliferator-activated receptor ligands reduce aortic dilatation in a mouse model of aortic aneurysm.
Topics: Angiotensin II; Animals; Aortic Aneurysm, Abdominal; Apolipoproteins E; Fenofibrate; Immunohistochem | 2010 |
Fenofibrate increases high-density lipoprotein and sphingosine 1 phosphate concentrations limiting abdominal aortic aneurysm progression in a mouse model.
Topics: Angiotensin II; Animals; Aorta; Aorta, Thoracic; Aortic Aneurysm, Abdominal; Apoptosis; Azo Compound | 2012 |